spacer
home > ebr > summer 2003 > making the remarkable routine
PUBLICATIONS
European Biopharmaceutical Review

Making the Remarkable Routine

Mass spectrometry (MS) has become one of the most ubiquitous analytical techniques in use today. It represents a powerful tool in the study of all substances because it provides more information about the composition and structure of a substance from a smaller amount of sample than any other analytical technique.

Of all the MS techniques currently available, fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) is arguably the most powerful. It offers 10-100 times higher mass resolution, mass resolving power and mass accuracy than any other mass analysis technique. Alternatively, viewed only as a separation device, ultrahigh-resolution FT-ICR MS offers more than 100 times higher peak capacity than the most effective wet chemical separation methods. This makes it possible to analyse complex mixtures with no prior chromatography.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Alan Marshall, National High Magnetic Field Laboratory at Florida State University, USA and Dr Alan Street, Oxford Instruments Superconductivity, at Oxford Instruments, UK

Professor Alan G Marshall received his BA in Chemistry from Northwestern University and PhD in Physical Chemistry from Stanford University. Following faculty positions at University of British Columbia and Ohio State University, he moved to Florida State University in 1993, where he is Kasha Professor of Chemistry and Director of the Ion Cyclotron Resonance Program at the National High Magnetic Field Laboratory. He is best known for his co-invention and continuing leading development of fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry.

His recognitions include Fellow in the American Physical Society and the American Association for the Advancement of Science; three national awards from the American Chemical Society; and awards from the Spectroscopy Society of Pittsburgh, the American Society for Mass Spectrometry and the International Society for Mass Spectrometry. In addition Professor Marshall is widely published.


Dr Alan Street gained a degree in Physics from the University of Wales and a DPhil from the University of York. His working life has focused on the development and exploitation of technology, having started in 1975 with GEC at their Hirst Research Centre in Wembley.

He moved to Marconi Elliot Avionics at Boreham Wood and then on to Sperry Gyroscope in Bracknell to join a team developing a new navigational technology based on laser gyroscopes. Joining Oxford Instruments Superconductivity in 1982, Alan is now Technical Director and Deputy Managing Director.


spacer
Professor Alan G Marshall
spacer
spacer
spacer
Dr Alan Street
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces New Integrated Plug & Play Upstream Development Service

Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up Tailored upstream development from a single source reduces time to clinic by 20 percent Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement